{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System",
        "BD Phoenix\u2122 Automated Microbiology System Levofloxacin (0.25-16 \u00b5g/mL) - Streptococcus ID/AST or AST"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K050747",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020322",
        "K020323"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "April 29, 2005",
    "Summary Letter Received Date": "March 22, 2005",
    "Submission Date": "March 18, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Levofloxacin"
    ],
    "Specimen Type(s)": [
        "Isolates from pure culture of aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria",
        "Streptococcal species"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth based microdilution test",
        "Redox indicator-based detection",
        "Continuous incubation and automated readings"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing (AST)",
        "Minimum inhibitory concentration (MIC) determination",
        "Organism identification (ID) testing"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent",
        "Instrument",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix\u2122M Automated Microbiology System with levofloxacin antimicrobial susceptibility testing for streptococcal isolates",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility (MIC) of most Gram-negative and Gram-positive bacteria isolates from pure culture, including addition of levofloxacin (0.25-16 \u03bcg/mL) to Streptococcus ID/AST or AST only Phoenix panels.",
    "fda_folder": "Microbiology"
}